Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome
PR Newswire
NEW YORK, July 1, 2026
New npj Parkinson's Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that behaviourally driven brain plasticity likely enhances the efficacy of dopaminergic treatment and provides both clinical and neurobiological benefits These findings further strengthen the mechanistic and translational rationale of Hybridopa™ and support its progression toward a Phase III clinical trialNEW YORK, July 1, 2026 /PRNewswire/ -- Remepy, a pioneer in Hybrid Drugs™, today announced the publication of new mechanistic findings in npj Parkinson's Disease (Nature Portfolio). The study provides insight, for the first time, into how Hybridopa™, Remepy's Hybrid Drug for the treatment of Parkinson's disease, may enhance the motor improvements previously observed and reported in Remepy's Phase IIa trial, through multimodal digital interventions, that combine evidence-based training activities with neuroscience-informed tools aimed at promoting brain plasticity.
